Identification
- Generic Name
- gamma-Glutamylcysteine
- DrugBank Accession Number
- DB03408
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for gamma-Glutamylcysteine (DB03408)
- Weight
- Average: 250.272
Monoisotopic: 250.062342258 - Chemical Formula
- C8H14N2O5S
- Synonyms
- 5-L-Glutamyl-L-cysteine
- gamma-Glu-Cys
- gamma-L-Glutamyl-L-cysteine
- Glu(-Cys)
- L-gamma-glutamyl-L-cysteine
- L-gamma-Glutamylcysteine
- γGluCys
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGlutathione synthetase Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Glutamate Metabolism Metabolic Hyperinsulinism-Hyperammonemia Syndrome Disease gamma-Glutamyltranspeptidase Deficiency Disease 2-Hydroxyglutric Aciduria (D and L Form) Disease gamma-Glutamyltransferase Deficiency Disease 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency Disease beta-Mercaptolactate-Cysteine Disulfiduria Disease 5-Oxoprolinase Deficiency Disease Succinic Semialdehyde Dehydrogenase Deficiency Disease Cysteine Metabolism Metabolic Glutathione Metabolism Metabolic 5-Oxoprolinuria Disease Glutathione Synthetase Deficiency Disease Homocarnosinosis Disease Cystinosis, Ocular Nonnephropathic Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- N-acyl-alpha amino acids
- Alternative Parents
- Cysteine and derivatives / L-alpha-amino acids / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Amino acids / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Carboximidic acids / Alkylthiols / Organopnictogen compounds show 4 more
- Substituents
- Aliphatic acyclic compound / Alkylthiol / Alpha-amino acid / Amine / Amino acid / Carbonyl group / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid / Cysteine or derivatives show 16 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- gamma-glutamylcysteine (CHEBI:17515)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- M984VJS48P
- CAS number
- 636-58-8
- InChI Key
- RITKHVBHSGLULN-WHFBIAKZSA-N
- InChI
- InChI=1S/C8H14N2O5S/c9-4(7(12)13)1-2-6(11)10-5(3-16)8(14)15/h4-5,16H,1-3,9H2,(H,10,11)(H,12,13)(H,14,15)/t4-,5-/m0/s1
- IUPAC Name
- (2S)-2-amino-4-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}butanoic acid
- SMILES
- N[C@@H](CCC(=O)N[C@@H](CS)C(O)=O)C(O)=O
References
- Synthesis Reference
Hiroaki Nishiuchi, "Method for producing gamma-glutamylcysteine." U.S. Patent US20030124684, issued July 03, 2003.
US20030124684- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0001049
- KEGG Compound
- C00669
- PubChem Compound
- 123938
- PubChem Substance
- 46506032
- ChemSpider
- 110467
- ChEBI
- 17515
- ChEMBL
- CHEMBL460831
- ZINC
- ZINC000003870040
- PDBe Ligand
- 3GC
- Wikipedia
- Gamma-Glutamylcysteine
- PDB Entries
- 1m0w / 2bu3 / 3kak / 4x8d / 5oes
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.62 mg/mL ALOGPS logP -2.5 ALOGPS logP -3.8 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 1.91 Chemaxon pKa (Strongest Basic) 9.24 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 129.72 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 56.31 m3·mol-1 Chemaxon Polarizability 23.36 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6298 Blood Brain Barrier + 0.8694 Caco-2 permeable - 0.8469 P-glycoprotein substrate Non-substrate 0.7613 P-glycoprotein inhibitor I Non-inhibitor 0.9517 P-glycoprotein inhibitor II Non-inhibitor 0.9886 Renal organic cation transporter Non-inhibitor 0.9576 CYP450 2C9 substrate Non-substrate 0.8399 CYP450 2D6 substrate Non-substrate 0.8295 CYP450 3A4 substrate Non-substrate 0.7275 CYP450 1A2 substrate Non-inhibitor 0.9496 CYP450 2C9 inhibitor Non-inhibitor 0.9364 CYP450 2D6 inhibitor Non-inhibitor 0.9342 CYP450 2C19 inhibitor Non-inhibitor 0.9427 CYP450 3A4 inhibitor Non-inhibitor 0.8919 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9905 Ames test AMES toxic 0.7948 Carcinogenicity Non-carcinogens 0.9386 Biodegradation Ready biodegradable 0.8085 Rat acute toxicity 1.5829 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9946 hERG inhibition (predictor II) Non-inhibitor 0.9654
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 161.4578058 predictedDarkChem Lite v0.1.0 [M-H]- 161.5295058 predictedDarkChem Lite v0.1.0 [M-H]- 161.3289058 predictedDarkChem Lite v0.1.0 [M-H]- 161.3575058 predictedDarkChem Lite v0.1.0 [M-H]- 155.29776 predictedDeepCCS 1.0 (2019) [M+H]+ 160.3565058 predictedDarkChem Lite v0.1.0 [M+H]+ 156.2805441 predictedDarkChem Standard v0.1.0 [M+H]+ 160.2429058 predictedDarkChem Lite v0.1.0 [M+H]+ 160.2652058 predictedDarkChem Lite v0.1.0 [M+H]+ 157.65579 predictedDeepCCS 1.0 (2019) [M+Na]+ 160.4274058 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.4082058 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.2889058 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.3542058 predictedDarkChem Lite v0.1.0 [M+Na]+ 163.74893 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein homodimerization activity
- Specific Function
- Not Available
- Gene Name
- GSS
- Uniprot ID
- P48637
- Uniprot Name
- Glutathione synthetase
- Molecular Weight
- 52384.325 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52